Biofrontera (BFRI) Total Non-Current Liabilities (2020 - 2026)
Biofrontera (BFRI) posted quarterly Total Non-Current Liabilities of $18.1 million for Q4 2025, up 10.09% year-over-year from $16.4 million in Q4 2024, and up 0.51% quarter-over-quarter from $18.0 million in Q3 2025.
Biofrontera (BFRI) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Biofrontera's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $18.1 million for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 10.09% year-over-year to $18.1 million; the TTM figure through Dec 2025 stood at $18.1 million (up 10.09% YoY), while the FY2025 annual figure was $18.1 million, up 10.09% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $18.1 million, up from $18.0 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $29.0 million in Q4 2021, with the low at -$9.4 million in Q2 2023.
- The 5-year median for Total Non-Current Liabilities is $18.0 million (2025), against an average of $16.2 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 441.27% in 2022, then tumbled 133.23% in 2023.
- Biofrontera's Total Non-Current Liabilities stood at $29.0 million in 2021, then declined by 7.03% to $27.0 million in 2022, then dropped by 29.85% to $18.9 million in 2023, then decreased by 13.27% to $16.4 million in 2024, then increased by 10.09% to $18.1 million in 2025.
- Business Quant data shows BFRI's Total Non-Current Liabilities at $18.1 million in Q4 2025, $18.0 million in Q3 2025, and $24.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Biofrontera | 18.87 Mn | 14.16 Mn | 9.59 Mn | 17.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.58 Mn |
| Dec 31, 2025 | 18.08 Mn |
| Sep 30, 2025 | 17.98 Mn |
| Jun 30, 2025 | 24.80 Mn |
| Mar 31, 2025 | 16.10 Mn |
| Dec 31, 2024 | 16.42 Mn |
| Sep 30, 2024 | 11.39 Mn |
| Jun 30, 2024 | 9.74 Mn |
| Mar 31, 2024 | 14.69 Mn |
| Dec 31, 2023 | 18.93 Mn |
| Sep 30, 2023 | 23.36 Mn |
| Jun 30, 2023 | -9.42 Mn |
| Mar 31, 2023 | 15.98 Mn |
| Dec 31, 2022 | 26.99 Mn |
| Sep 30, 2022 | 26.82 Mn |
| Jun 30, 2022 | 28.35 Mn |
| Mar 31, 2022 | 27.64 Mn |
| Dec 31, 2021 | 29.03 Mn |
| Sep 30, 2021 | 23.43 Mn |
| Jun 30, 2021 | -8.60 Mn |